DDrare: Database of Drug Development for Rare Diseases

37. 膿疱性乾癬（汎発型）
［臨床試験数：58，薬物数：50（DrugBank：18），標的遺伝子数：17，標的パスウェイ数：96］

Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AIN457; AIN457, 150mg; ANAKINRA; ANB019; Acitretin; Adalimumab; Alefacept; Alvarez 2; Anakinra; Anti-IL-36R monoclonal antibody; BI 655130; BI655130; Brodalumab; Brodalumab 210mg SC; CNTO1959; Calcitriol; Certolizumab Pegol; Certolizumab pegol; Efalizumab; GUSELKUMAB; Guselkumab; Guselkumab 100 mg; Infliximab; Infliximab [infliximab biosimilar 3]; Ixekizumab; KHK4827; KHK4827 140mg SC; KHK4827 210mg SC; LY3074828; MONOCLONAL ANTIBODY ANTI-IGG1; Mirikizumab; Null; P32; P32/98; P32/98 3%; Placebo; Raptiva; Risankizumab; SECUKINUMAB; Secukinumab; Secukinumab 150 mg/1 mL Solution for injection; Secukinumab 150mg; Secukinumab 300mg; Silikis 3µg/g Salbe; Spesolimab; TA-650; TG; TREMFYA®; Tremfya; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03619902 (ClinicalTrials.gov)	March 4, 2019	19/7/2018	A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis	A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis	Generalized Pustular Psoriasis	Drug: ANB019	AnaptysBio, Inc.	NULL	Active, not recruiting	18 Years	75 Years	All	10	Phase 2	United States;Korea, Republic of;Poland;United Kingdom
2	EUCTR2017-004021-33-GB (EUCTR)	04/05/2018	20/12/2017	To Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis	A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis - ANB019-002 - Generalized Pustular Psoriasis	Generalized Pustular Psoriasis (GPP) MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Psoriasis pustular;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10	Phase 2	United States;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03619902
(ClinicalTrials.gov)

March 4, 2019

19/7/2018

A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

Drug: ANB019

AnaptysBio, Inc.

NULL

Active, not recruiting

18 Years

75 Years

All

Phase 2

United States;Korea, Republic of;Poland;United Kingdom

EUCTR2017-004021-33-GB
(EUCTR)

04/05/2018

20/12/2017

To Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis - ANB019-002 - Generalized Pustular Psoriasis

Generalized Pustular Psoriasis (GPP)
MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Psoriasis pustular;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

AnaptysBio Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;United Kingdom